Michael D. Greicius
Stanford
Functional MRI currently has few clinical
applications. This is due, in part, to the difficulty of using
task-activation fMRI in a clinical setting. Resting-state fMRI, which allows
for the detection of 15-20 large-scale brain networks, has the potential to
overcome some of these clinical limitations. This talk will examine efforts
to develop resting-state fMRI biomarkers for several neuropsychiatric
disorders including coma, depression and chronic pain. Particular emphasis
will be placed on resting-state fMRI as a potential biomarker in Alzheimers
disease.